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Abstract
Background
To evaluate the impact of macrophage activation syndrome (MAS) on clinical features in
patients with Kikuchi-Fujimoto disease (KFD) and to compare the features of MAS in KFD
with those of adult-onset Still’s disease (AOSD) and systemic lupus erythematosus (SLE).
Methods
The medical records of febrile patients hospitalised with KFD between November 2005 and
April 2017 were reviewed. Patients fulfilling the 2016 classification criteria for MAS were
classified as having MAS. Clinical and laboratory features of patients with KFD with and
without MAS were evaluated. Poor hospitalisation outcomes were defined as intensive care
unit admission or in-hospital mortality. The treatment outcomes of MAS in KFD, AOSD, and
SLE were also compared.
Results
Among 78 patients hospitalised with KFD, 24 (30.8%) patients had MAS during admission.
Patients with KFD and MAS more frequently required glucocorticoid treatment (66.7% vs
40.7%, p = 0.036) and had longer hospital stays than patients with KFD without MAS (12.5
vs 8.5 days, p<0.001). In addition, patients with MAS had worse hospitalisation outcomes
than patients without MAS (29.2% vs. 0.0%, p<0.001). Among patients with MAS in KFD,
AOSD, and SLE, the number of patients requiring glucocorticoid treatment after 3 months
was significantly lower among patients with MAS and KFD (KFD 33.3%, AOSD 88.9%, SLE
100%, p<0.001).
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Conclusions
The presence of MAS in KFD was associated with adverse clinical outcomes including
higher steroid usage and worse hospitalisation outcomes. However, compared to those with
AOSD and SLE, patients with MAS and KFD were less likely to require long-term glucocorti-
coid treatment.
Introduction
Kikuchi-Fujimoto disease (KFD), also known as histiocytic necrotising lymphadenitis, is a rare
idiopathic inflammatory disease first described in 1972 by Kikuchi and Fujimoto et al [1, 2].
KFD mainly affects adults younger than 40 years of age and is predominant among Asian pop-
ulations [3]. The aetiology of KFD is still unknown although various inciting agents, including
the Epstein-Barr virus (EBV), human herpesvirus types 6, 7, and 8, herpes simplex virus, and
HIV, have been suggested as possible causative agents [1, 2, 4]. KFD typically presents as persis-
tent cervical lymphadenopathy with or without fever [5]. Some patients manifest non-specific
systemic symptoms including night sweats, weight loss, nausea, vomiting, hepatosplenomegaly,
and headache [6, 7]. The clinical characteristics of KFD can resemble those of malignant lym-
phoma, metastatic carcinoma, infectious lymphadenitis, systemic autoimmune diseases, and
Mycobacterium tuberculosis infections [8–10]. The overall prognosis of KFD is favourable with
a benign, self-limiting course. Although there is no specific treatment for KFD, supportive
management with analgesics and antipyretics is usually adequate, leading to spontaneous reso-
lution in several months [6].
In KFD cases with severe clinical presentations, few case reports described co-existence of
hemophagocytic lymphohistiocytosis (HLH) [11–18]. HLH is a syndrome of excessive proin-
flammatory cytokine production due to uncontrolled expansion of T lymphocytes and macro-
phages, which is characterised by hemophagocytosis, intractable fever, hepatosplenomegaly,
cytopenia, hypertriglyceridemia, and hypofibrinogenemia [19, 20]. Although primary HLH is
associated with genetic defects in the perforin-mediated cytolytic pathway, macrophage activa-
tion syndrome (MAS) is considered to be a secondary form of HLH associated with malig-
nancy, infection, and autoimmune diseases [21]. Because viral infections such as EBV are
known to cause HLH by triggering uncontrolled lymphoproliferation [22], there is a concern
that KFD can be associated with MAS. While MAS is a potentially life-threatening condition
that requires early detection, MAS-specific diagnostic criteria have not yet been fully estab-
lished. Recently, new classification criteria for MAS were developed by a collaboration of inter-
national study groups and were validated in patients with systemic juvenile idiopathic arthritis
(sJIA) with excellent specificity [23, 24]. We previously demonstrated that these criteria were
also useful for the identification of patients with MAS in adult-onset Still’s disease (AOSD)
and systemic lupus erythematosus (SLE) to predict poor hospitalisation outcomes [25, 26].
Although MAS may follow a severe and fatal course, the incidence and clinical characteris-
tics of MAS-complicated KFD are still not well understood. In our study, we aimed to evaluate
the impact of MAS on the clinical features of KFD and to compare the clinical and laboratory
features of patients with MAS complicating KFD, AOSD, and SLE.
Material and methods
Patient selection and study design
We retrospectively reviewed the clinical and laboratory data of patients with a diagnosis of
KFD between November 2005 and April 2017 in two tertiary hospitals in the Yonsei University
MAS in Kikuchi disease
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Health System located in Shinchon and Gangnam district of Seoul, Korea. The inclusion crite-
ria were as follows: (i) patients who were admitted with fever; (ii) patients with diagnosis of
KFD that was confirmed pathologically; (iii) patients with ferritin level assessment; (iv)
patients without concurrent autoimmune disease/infection. Finally, 78 patients were included
in this study. The flowchart for patient selection is shown in S1 Fig. The clinical and laboratory
data of patients with MAS in AOSD and SLE according to the 2016 classification criteria were
obtained using a pre-existing dataset used in a previous study [25, 26], and all data were fully
anonymized for analysis. This study was conducted in accordance with the Declaration of Hel-
sinki and was approved by the Institutional Review Board of Severance Hospital (IRB approval
number 4-2018-0624). The requirement to obtain informed consent was waived because of the
retrospective nature of the study.
Definition of patients with MAS according to the 2016 classification
criteria
According to the 2016 EULAR/ACR/PRINTO classification criteria for MAS [23, 24], we clas-
sified patients as having MAS when they presented with fever, a ferritin level of�684 ng/mL,
and fulfilled more than 2 of the following 4 criteria: platelet count�181,000/mL, aspartate
aminotransferase (AST) level>48 units/L, triglyceride level>156 mg/dL, and fibrinogen level
�360 mg/dL. In addition, patients with MAS were divided into two groups: patients having
MAS on admission and those who developed MAS after admission.
Collection of clinical and laboratory variables
The clinical data collected included age, sex, length of hospital stay, in-hospital mortality,
intensive care unit admission, and treatment. Poor hospitalisation outcomes were defined as
intensive care unit admission or in-hospital mortality. The clinical manifestations of KFD
included the presence of hepatomegaly, splenomegaly, skin rash, and joint pain. Baseline labo-
ratory variables included white blood cells, neutrophils, lymphocyte and platelet counts, eryth-
rocyte sedimentation rate, and levels of haemoglobin, C-reactive protein (CRP), creatinine,
AST, alanine aminotransferase (ALT), albumin, ferritin, lactate dehydrogenase (LDH), fibrin-
ogen, and triglycerides. As fibrinogen and triglyceride levels were not measured regularly,
the levels obtained within 3 days of the date of laboratory data selection were included in the
analysis.
Calculation of the hemophagocytic syndrome score (HScore) and patients
fulfilling the HLH-2004 criteria
The HScore was developed to evaluate individual risk for the presence of hemophagocytic syn-
drome [27] and is also useful to identify the risk of having reactive hemophagocytic syndrome
in patients with rheumatic diseases [28]. The HScore and the probability of having hemopha-
gocytic syndrome were calculated using an online calculator (saintantoine.aphp.fr/score).
Furthermore, the proportion of patients fulfilling the HLH-2004 criteria was estimated as pre-
viously described [29].
Statistical analysis
Continuous variables were presented as medians with interquartile ranges (IQR), and categori-
cal variables were presented as frequencies and percentages. Continuous variables were com-
pared using the Kruskal–Wallis test or Mann–Whitney U test, and categorical variables were
compared using the chi-square or Fisher’s exact test, as appropriate. Kaplan-Meier analysis
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and the log-rank test were used to compare the survival probability among the groups. All sta-
tistical analyses were performed using MedCalc statistical software version 18.6 (MedCalc
Software, Ostend, Belgium) or GraphPad Prism software version 5.0 (GraphPad Software, San
Diego, California, USA). In all statistical analyses, a two-tailed p<0.05 was considered statisti-
cally significant.
Results
Baseline characteristics of patients with and without MAS
Of the 78 patients included in the study, 24 (30.8%) were classified as having MAS during
admission (Table 1). Among the 24 patients, 20 (83.3%) had MAS on admission, and 4
(16.7%) developed MAS after admission. Although the clinical manifestations were not dif-
ferent between patients with and without MAS, patients with MAS were older and had a lon-
ger hospital stays, and the proportion of patients with poor hospitalisation outcomes was
significantly higher in patients with MAS (29.2% vs. 0.0%, p<0.001). In addition, the median
HScore (97.0 [IQR 68.0–128.5] vs 49.0 [IQR 33.0–72.0]) and the probability of having hemo-
phagocytic syndrome were higher in patients with MAS than in patients without MAS (all
p<0.001) (Fig 1A and 1B). Furthermore, the proportion of patients requiring glucocorticoid
treatment was significantly higher in patients with MAS (66.7% vs 40.7%, p = 0.036). Regard-
ing laboratory findings, patients with MAS had higher CRP, ALT, and LDH levels and a
lower lymphocyte count and albumin levels than those without MAS. Among the laboratory
variables selected for MAS classification, higher AST and ferritin levels and lower platelet
counts were observed in patients with MAS; however, the differences between triglyceride
and fibrinogen levels were not significant (Table 2). Of the 19/78 (24.4%) patients who had
undergone a bone marrow study, only 2 patients in the MAS group were found to have
hemophagocytosis.
Table 1. Clinical characteristics of patients with KFD with and without MAS.
Without MAS (n = 54) With MAS (n = 24) p-value
Demographic data
Age, years 26.0 (21.0–35.0) 40.0 (32.5–55.0) <0.001
Female sex 37 (68.5) 15 (62.5) 0.605
Clinical manifestations
Hepatomegaly 6 (11.1) 0 (0.0) 0.169
Splenomegaly 12 (22.2) 7 (29.2) 0.512
Skin rash 8 (14.9) 7 (29.2) 0.140
Joint pain 1 (1.9) 3 (12.5) 0.084
Treatment
Glucocorticoid treatment 22 (40.7) 16 (66.7) 0.036
Immunosuppressive treatment 1 (1.9) 3 (12.5) 0.084
Hydroxychloroquine 1 (1.9) 2 (8.3)
Cyclosporine 0 (0.0) 1 (4.2)
Clinical course
Length of stay in hospital (days) 8.5 (6.0–11.0) 12.5 (10.5–32.0) <0.001
In-hospital mortality 0 (0.0) 5 (20.8) 0.002
Intensive unit care 0 (0.0) 7 (29.2) <0.001
Data expressed as median (interquartile range) or n (%). KFD, Kikuchi-Fujimoto disease; MAS, macrophage activation syndrome.
https://doi.org/10.1371/journal.pone.0219970.t001
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Clinical and laboratory findings of patients with KFD and in-hospital
mortality
As MAS in KFD is not a well-described complication, we further analysed the clinical and lab-
oratory features of patients with KFD and in-hospital mortality (Table 3). All patients in our
study who died in the hospital had MAS, were older than 50 years of age and did not have any
Fig 1. HScore and the probability of having hemophagocytic syndrome in patients with KFD with and without
MAS. Comparison of HScore (A) and the probability of having hemophagocytic syndrome (B) in patients with KFD
with and without MAS. HScore, hemophagocytic syndrome score; KFD, Kikuchi-Fujimoto disease; MAS, macrophage
activation syndrome.
https://doi.org/10.1371/journal.pone.0219970.g001
Table 2. Comparison of baseline laboratory findings of patients with and without MAS.
Variable Without MAS (n = 54) With MAS (n = 24) p-value
General laboratory variables
WBC count (/μL) 3475.0 (2350.0–5000.0) 3285.0 (2335.0–5905.0) 0.996
Hemoglobin (g/dL) 12.5 (11.7–13.4) 11.7 (10.3–13.2) 0.102
Neutrophil count (/μL) 1925.0 (1310.0–3050.0) 2206.5 (1375.0–4833.5) 0.378
Lymphocyte count (/μL) 1045.0 (860.0–1370.0) 600.0 (490.0–940.0) <0.001
ESR (mm/h) 48.5 (27.0–64.0) 52.5 (39.5–72.5) 0.242
CRP (mg/L) 15.0 (7.5–37.1) 52.6 (27.7–97.1) <0.001
Creatinine (mg/dL) 0.7 (0.6–0.8) 0.7 (0.5–1.1) 0.349
ALT (IU/L) 21.5 (14.0–38.0) 44.5 (23.0–153.0) 0.003
Albumin (g/dL) 4.0 (3.7–4.3) 3.4 (3.1–3.7) <0.001
LDH (IU/L) 439.5 (291.0–611.0) 771.5 (460.0–1213.5) 0.003
Laboratory variables selected for MAS classification
Platelet count (×1000/μL) 195.5 (155.0–260.0) 139.0 (94.5–184.0) <0.001
AST (IU/L) 29.0 (22.0–39.0) 93.5 (62.5–191.0) <0.001
Ferritin (ng/mL) 242.8 (112.0–405.2) 1449.7 (812.9–4463.1) <0.001
Triglyceride (mg/dL)¶ 89.0 (60.0–106.5) 133.0 (90.3–161.3) 0.076
Fibrinogen (mg/dL)§ 342.0 (338.0–346.0) 317.5 (227.5–401.0) 0.695
Bone marrow biopsy findings�
Presence of hemophagocytosis 0/7 (0.0) 2/12 (16.7) 0.509
Data are expressed as median (interquartile range) or n (%). MAS, macrophage activation syndrome; WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP,
C-reactive protein; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; AST, aspartate aminotransferase.
¶Number confined to patients who underwent each test (n = 23).
§Number confined to patients who underwent each test (n = 10).
�Number confined to patients who underwent each test (n = 19).
https://doi.org/10.1371/journal.pone.0219970.t002
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specific clinical manifestations. Among MAS patients with KFD (n = 24), patients aged�50
years had a higher mortality rate than those aged<50 years (p = 0.003) (Fig 2). During the dis-
ease course, patients with MAS had increasing ferritin and AST levels, while platelet counts
decreased. Most deaths occurred within 90 days, and among the five patients who died, the
cause of death was multi-organ failure in 4 patients and sepsis in 1 patient (Table 3). Hepatos-
plenomegaly was only observed in one patient, and no patients had co-existing comorbidities
with the exception of gout in one patient.
Clinical and laboratory features among patients with MAS in KFD, AOSD,
and SLE
Next, we compared the clinical and laboratory features among patients with MAS in KFD,
AOSD and SLE. Clinical and laboratory data of patients with AOSD or SLE and MAS used for
comparison were obtained from the dataset of previous studies [25, 26]. Patients with AOSD
were older than those with SLE, and the proportion of female patients was the lowest in
patients with KFD. The presence of lymphadenopathy was significantly higher in patients with
KFD than in those with AOSD or SLE (Table 4). There were no differences in the median
HScore (KFD 97.0 [IQR 68.0–128.5] vs AOSD 108.5 [IQR 102.0–150.0] vs SLE 111.0 [IQR
76.0–137.0], p = 0.296) or the probability of having hemophagocytic syndrome among patients
with MAS in KFD, AOSD, and SLE (S2A and S2B Fig, p = 0.296). In addition, the number of
patients fulfilling the HLH-2004 criteria was 2/24 (8.3%), 6/36 (16.7%), and 3/54 (5.6%) in
KFD, AOSD, and SLE, respectively, without a statistical difference (p = 0.210). Comparison of
laboratory variables between the groups showed that elevated white blood cells, neutrophils,
lymphocyte count, and CRP levels were prominent in patients with AOSD, while decreased
haemoglobin and albumin levels were characteristic in patients with SLE. Regarding laboratory
variables selected for MAS classification, platelet count and ferritin levels were the highest in
patients with AOSD, while triglyceride levels were the lowest in patients with KFD (Table 4).
Comparison of 90-day mortality and treatment among patients with MAS
in KFD, AOSD, and SLE
To evaluate the prognosis of patients with MAS in different diseases, we compared the 90-day
mortality among patients with MAS in KFD, AOSD, and SLE by using Kaplan-Meier analysis
with the log-rank test. The number of patients with 90-day mortality in KFD, AOSD, and SLE
was 4 (16.7%), 12 (33.3%), and 15 (27.8%) patients, respectively. Kaplan-Meier survival analy-
sis showed that the survival probability among patients with MAS in KFD, AOSD, and SLE
Table 3. The clinical and laboratory features of patients with KFD and in-hospital mortality.
Case
number
Age/Sex Main symptom Initial/highest ferritin level
(ng/mL)
Initial/lowest platelet
count (/μL)
Initial/highest AST
level (IU/L)
Time to death
(days)
Cause of death
1 68/Male Fever 13308.3/15000.0 133000/27000 178/24650 Death in day 8 Multi-organ
failure
2 52/
Female
Fever, skin rash,
joint pain
14399.9/14399.9 69000/20000 132/134 Death in day 11 Multi-organ
failure
3 56/Male Fever, myalgia 441.8/1896.6 346000/7000 204/8320 Death in day 24 Sepsis
4 61/
Female
Fever, headache,
nausea
15363.6/15363.6 92000/16000 96/394 Death in day 32 Multi-organ
failure
5 57/
Female
Sore throat, fever 528.9/38765.3 97000/21000 22/483 Death in day
281
Multi-organ
failure
KFD, Kikuchi-Fujimoto disease.
https://doi.org/10.1371/journal.pone.0219970.t003
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was not statistically significant (p = 0.427) (S3 Fig). However, the treatment for patients with
KFD, AOSD, and SLE was different according to the underlying disease, and patients with
KFD had a higher rate of glucocorticoid cessation after 3 months (KFD 66.7%, AOSD 11.1%,
SLE 0.0%, p<0.001) and had fewer immunosuppressive agents administered (Table 4).
Fig 2. Comparison of the overall survival rate of patients with KFD and MAS according to age. In MAS patients
with KFD, patients aged�50 years had a higher mortality rate than those aged<50 years. KFD, Kikuchi-Fujimoto
disease; MAS, macrophage activation syndrome.
https://doi.org/10.1371/journal.pone.0219970.g002
MAS in Kikuchi disease
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Discussion
While KFD is pathologically characterised by a proliferation of activated cytotoxic T lympho-
cytes and histiocytes with central necrotic areas in lymph nodes, HLH is characterised by
hemophagocytosis, engulfing erythrocytes, and leukocytes by histiocyte in the bone marrow or
Table 4. Clinical and laboratory features in patients with MAS in KFD, AOSD, and SLE.
Variable KFD (n = 24) AOSD (n = 36) SLE (n = 54) p-value
Demographic data
Age, years 40.0 (32.5–55.0) 47.5 (36.0–57.5)�� 37.0 (26.0–49.0) 0.010
Female sex 15 (62.5)b 34 (94.4) 46 (85.2)§ 0.004
Clinical manifestations
Hepatomegaly 0 (0.0) 4 (11.1) 8 (14.8) 0.143
Splenomegaly 7 (29.2) 10 (27.8) 16 (29.6) 0.982
Lymphadenopathy 24 (100.0)c 16 (44.4) 29 (53.7)§§§ <0.001
General laboratory variables
WBC count (/μL) 3285.0 (2335.0–5905.0)c 10630.0 (6915.0–6130.0)��� 2830.0 (1800.0–6210.0) <0.001
Hemoglobin (g/dL) 11.7 (10.3–13.2) 10.9 (10.0–11.7)�� 10.1 (8.7–11.0)§§§ <0.001
Neutrophil count (/μL) 2206.5 (1375.0–4833.5)c 8575.0 (4780.0–14325.0)��� 2015.0 (1230.0–4320.0) <0.001
Lymphocyte count (/μL) 600.0 (490.0–940.0)a 899.0 (655.0–1225.0)��� 491.4 (310.0–790.0) <0.001
ESR (mm/h) 52.5 (39.5–72.5) 61.0 (29.0–83.0) 42.5 (29.0–70.0) 0.186
CRP (mg/L) 52.6 (27.7–97.1)a 96.4 (50.2–143.8)��� 13.5 (5.5–59.9)§§ <0.001
ALT (IU/L) 44.5 (23.0–153.0) 36.0 (23.5–117.5) 38.5 (24.0–68.0) 0.729
Albumin (g/dL) 3.4 (3.1–3.7) 3.1 (3.0–3.6)� 2.9 (2.4–3.3)§§ 0.011
Laboratory variables selected for MAS classification
Platelet count (×1000/μL) 139.0 (94.5–184.0)a 203.5 (140.0–292.0)��� 109.5 (91.0–155.0) <0.001
AST (IU/L) 93.5 (62.5–191.0) 76.5 (42.0–207.5) 89.0 (50.0–183.0) 0.778
Ferritin (ng/mL) 1449.7 (812.9–4463.1)b 6773.4 (2567.1–14610.2)��� 1483.5 (754.9–2324.7) <0.001
Triglyceride (mg/dL) 133.0 (90.3–161.3) 168.0 (126.7–223.5) 173.0 (145.5–274.0)§§ 0.026
Fibrinogen (mg/dL) 317.5 (227.5–401.0) 302.0 (202.5–406.3) 253.0 (170.0–329.0) 0.320
Clinical course and treatment outcome
Length of stay in hospital (days) 12.5 (10.5–32.0) 22.5 (13.0–41.5) 19.0 (14.0–29.0) 0.257
Glucocorticoid treatment cessation at 3 months† 16 (66.7)c 4 (11.1)� 0 (0.0)§§§ <0.001
Number of Immunosuppressive treatments administered‡ 0.018
0–1 24 (100.0)b 26 (72.2) 45 (83.3)§
�2 0 (0.0) 10 (27.8) 9 (16.7)
Data expressed as median (interquartile range) or n (%).
†Glucocorticoid treatment and the dosage of glucocorticoids in patients with mortality or who were lost to follow-up were counted on the last date of follow-up.
‡Includes treatment with disease modifying anti-rheumatic drugs, biologics, cyclosporine, and etoposide/cyclophosphamide.
aDifference between patients with KFD and AOSD. p < 0.05;
bDifference between patients with KFD and AOSD, p < 0.01;
cDifference between patients with KFD and AOSD, p < 0.001.
§Difference between patients with KFD and SLE. p < 0.05;
§§Difference between patients with KFD and SLE, p < 0.01;
§§§Difference between patients with KFD and SLE, p < 0.001.
�Difference between patients with AOSD and SLE, p < 0.05;
��Difference between patients with AOSD and SLE, p < 0.01;
���Difference between patients with AOSD and SLE, p < 0.001.
MAS, macrophage activation syndrome; KFD, Kikuchi-Fujimoto disease; AOSD, adult onset Still’s disease; SLE, systemic lupus erythematosus; WBC, white blood cell;
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
https://doi.org/10.1371/journal.pone.0219970.t004
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liver. Therefore, both KFD and HLH are associated with abnormal histiocyte activation. In
addition, inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1,
and IL-6 are also implicated in the pathogenesis of both MAS and severe cases of KFD [30, 31].
Therefore, although it is possible that HLH can be accompanied by KFD, the association
between KFD and HLH is not well understood. In this study, by using the 2016 EULAR/ACR/
PRINTO classification criteria, we found the incidence of MAS, a secondary form of HLH,
was 30.8% in our study population of pathologically confirmed KFD. Because we included
only febrile hospitalised patients with KFD, our study population might have been skewed
towards those having severe laboratory abnormalities in tertiary referral centres; however, the
association of MAS in KFD is an interesting finding that requires clinical attention.
KFD patients with MAS experienced longer hospital stays and worse hospitalisation out-
comes, including higher rates of intensive care unit stays and in-hospital mortality than in
patients without MAS. In addition, the proportion of patients with KFD requiring glucocorti-
coid treatment was significantly higher in patients with MAS than in patients without MAS.
All 5 cases of mortality in our cohort were observed in patients with MAS who were over the
age of 50. Compared to patients aged<50 years, those aged 50 years and older had signifi-
cantly higher mortality in KFD with MAS. These findings suggest that older KFD patients with
MAS might be especially associated with poor prognosis.
MAS presents as non-remitting fever, generalised lymphadenopathy, hepatosplenomegaly,
pancytopenia, high ferritin, and low fibrinogen levels [32]. Since there are no disease-specific
clinical manifestations or laboratory abnormalities of MAS, and many of the symptoms resem-
ble those of KFD itself, the clinician’s suspicion is critical for the diagnosis. In addition, even
though hyperferritinemia is a prerequisite in the 2016 criteria for MAS, alternative diagnoses
which can be associated with elevated ferritin levels such as sepsis and catastrophic antipho-
spholipid syndrome should be excluded [33]. In our study, the difference in clinical manifesta-
tions between patients with KFD with and without MAS was not significant. On the other
hand, in terms of laboratory findings, patients with KFD and MAS had higher CRP, LDH, fer-
ritin, AST, and ALT levels and lower platelet counts, lymphocyte count, and albumin levels
than patients with KFD without MAS. Importantly, in our study, a higher proportion of
patients with KFD and MAS were treated with steroids than patients without MAS. Monitor-
ing for MAS in patients with KFD could be clinically important, as patients without MAS
could be treated with supportive care, while those with MAS might require steroids or addi-
tional second-line treatments such as cyclosporine, anti-cytokine therapy, or chemotherapy
[34].
Comparison of clinical and laboratory features between patients with MAS-associated
KFD, AOSD, and SLE showed that they had different characteristics. Notably, a higher propor-
tion of patients with KFD were able to stop steroids within 3 months compared to patients
with SLE or AOSD. Additionally, fewer immunosuppressive agents were administered to
patients with MAS and KFD than to patients with MAS and AOSD or SLE. Hence, the clinical
course of MAS-associated KFD is milder than MAS with SLE or AOSD, suggesting that the
treatment of MAS should be tailored to the underlying diseases.
In our data, 50% (12/24) of KFD patients with MAS received bone marrow evaluation and
only 16.7% (2/12) patients were found to have hemophagocytosis. Although this is a small
number of patients in a retrospective study, the incidence of hemophagocytosis in our KFD
patients were lower than other studies with autoimmune diseases. In a recent review paper of
MAS with autoimmune diseases, 42%-100% were positive for bone marrow hemophagocytosis
in patients with SLE, Kawasaki disease, and sJIA [35]. In our recent MAS study with AOSD
patients, 50% was positive for hemophagocytosis in bone marrow evaluation [26]. It is possible
that our KFD patients might have received bone marrow biopsy in the early course which
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often makes the result negative [21]. It is also possible that macrophage activation in lymph
nodes might be enough to drive MAS in KFD. Although in the autoimmune area, bone mar-
row analysis is not always required for diagnosis of MAS, it is of interest to validate our finding
in future studies.
The strength of this study is that, to our knowledge, it is the first study to investigate the
incidence and clinical outcomes of MAS in patients with KFD. We only included patients
whose diagnoses were confirmed pathologically, further validating our results. Since KFD is
prevalent in young Asian women, we have a large population of patients with KFD at our insti-
tution, enabling recruitment of a statistically significant number of patients for this study.
However, our study also has several limitations. First, it is a retrospective study, and the data
were collected by reviewing the hospital’s medical records. Second, there were patients who
did not have ferritin, fibrinogen, and triglyceride level results; this might have influenced
patient selection and classification resulting in selection bias because clinically severe patients
may undergo more blood tests. Therefore, the incidence of MAS in our study might be rele-
vant in patients with KFD and severe clinical or laboratory features. Third, data regarding pro-
inflammatory cytokines (TNF-α, interferon-γ, IL-1, IL-6, and soluble CD163) associated with
MAS were not obtainable because the following tests were not available in our hospitals [36,
37]. Because these cytokines are known to play an important role in the pathogenesis of MAS
[30, 31], assessment of such tests in future studies would provide additional significance.
Fourth, because the 2016 classification criteria for MAS have only been validated in patients
with sJIA, caution should be made when applying the criteria to non-sJIA diseases. HLH-2004
criteria may be more suitable for non-sJIA diseases. Because a majority of patients had not
undergone tests of bone marrow study, natural killer cell activity, and soluble CD25, we could
not validate our finding using HLH-2004 criteria.
In conclusion, our findings suggest that the application of the 2016 EULAR/ACR/PRINTO
criteria for MAS in hospitalised patients with KFD can be useful in detecting MAS. In addi-
tion, although the clinical and laboratory findings were different based on the underlying auto-
immune disease, the presence of MAS based on the 2016 EULAR/ACR/PRINTO criteria was
associated with adverse patient prognosis. Especially older patients with KFD who presents
with features of MAS may be associated with a high mortality rate and may need special atten-
tion. Therefore, monitoring patients with KFD according to the 2016 criteria for MAS might
aid in predicting patient prognosis and the stratification of high-risk patients.
Supporting information
S1 Fig. Flowchart for patient selection. The flowchart for patient inclusion.
(TIF)
S2 Fig. HScore and the probability of having hemophagocytic syndrome among patients
with MAS in KFD, AOSD, and SLE. Comparison of HScore (A) and the probability of having
hemophagocytic syndrome (B) in patients with MAS and KFD, AOSD, or SLE. HScore; hemo-
phagocytic syndrome score; MAS, macrophage activation syndrome; KFD, Kikuchi-Fujimoto
disease; AOSD, adult onset Still’s disease; SLE, systemic lupus erythematosus.
(TIF)
S3 Fig. Kaplan-Meier survival curve of 90-day mortality among patients with MAS in
KFD, AOSD, and SLE. Comparison of survival probability among patients with MAS in KFD,
AOSD, and SLE. MAS, macrophage activation syndrome; KFD, Kikuchi-Fujimoto disease;
AOSD, adult onset Still’s disease; SLE, systemic lupus erythematosus.
(TIF)
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